Intrinsic Imaging Awarded Interventional Medical Device Trial for Prevention of Pulmonary Emboli
March 3, 2015 - Boston, MA, San Antonio, TX - Intrinsic Imaging, an FDA audited, ISO 9001:2008 and ISO 13485:2003certified, GAMP® 5 compliant medical imaging core lab specializing in providing services for clinical trials, announced today that it has been awarded a clinical trial to study an interventional medical device designed for the prevention of pulmonary emboli.
Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, protocol and charter development, site qualification, site training and management, image transfer, blinding and processing as well as the specialized radiologic review of images.
Intrinsic Imaging is the only imaging core lab that is ISO 13485 certified specifically to provide quality services for medical device clinical trials. The company’s team of full-time, board-certified, fellowship-trained interventional radiologists have experience assessing medical devices including, but not limited to, catheters, stents, angioplasty balloons, thrombectomy devices, venous access tools, novel devices and biologics.
Importantly, in addition to device assessment, Intrinsic Imaging is able to guide in the development of the imaging charter and provide expertise in the selection of imaging modalities and acquisition protocols that are best oriented towards the placement, assessment and evaluation of medical devices.
“We are pleased to have been chosen to apply our medical device expertise to this trial,” said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging. “Acute pulmonary emboli are the most serious clinical presentation of venous thromboembolic disease and a major cause of hospitalization, morbidity and mortality. Intrinsic Imaging brings Sponsors unprecedented expertise in the management of medical device clinical trials.”
Intrinsic Imaging’s medical device certification was granted by the British Standards Institute (BSI), one of the world’s largest certification bodies.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
